Literature DB >> 21155744

Competing risks regression for stratified data.

Bingqing Zhou1, Aurelien Latouche, Vanderson Rocha, Jason Fine.   

Abstract

For competing risks data, the Fine-Gray proportional hazards model for subdistribution has gained popularity for its convenience in directly assessing the effect of covariates on the cumulative incidence function. However, in many important applications, proportional hazards may not be satisfied, including multicenter clinical trials, where the baseline subdistribution hazards may not be common due to varying patient populations. In this article, we consider a stratified competing risks regression, to allow the baseline hazard to vary across levels of the stratification covariate. According to the relative size of the number of strata and strata sizes, two stratification regimes are considered. Using partial likelihood and weighting techniques, we obtain consistent estimators of regression parameters. The corresponding asymptotic properties and resulting inferences are provided for the two regimes separately. Data from a breast cancer clinical trial and from a bone marrow transplantation registry illustrate the potential utility of the stratified Fine-Gray model.
© 2010, The International Biometric Society.

Entities:  

Mesh:

Year:  2010        PMID: 21155744      PMCID: PMC3431205          DOI: 10.1111/j.1541-0420.2010.01493.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  8 in total

1.  Competing risks as a multi-state model.

Authors:  Per Kragh Andersen; Steen Z Abildstrom; Susanne Rosthøj
Journal:  Stat Methods Med Res       Date:  2002-04       Impact factor: 3.021

2.  Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function.

Authors:  John P Klein; Per Kragh Andersen
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

3.  Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution.

Authors:  Sandrine Katsahian; Matthieu Resche-Rigon; Sylvie Chevret; Raphaël Porcher
Journal:  Stat Med       Date:  2006-12-30       Impact factor: 2.373

4.  Competing risks analysis of correlated failure time data.

Authors:  Bingshu E Chen; Joan L Kramer; Mark H Greene; Philip S Rosenberg
Journal:  Biometrics       Date:  2007-08-03       Impact factor: 2.571

5.  Analyses of cumulative incidence functions via non-parametric multiple imputation.

Authors:  Ping K Ruan; Robert J Gray
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

6.  A semiparametric random effects model for multivariate competing risks data.

Authors:  Thomas H Scheike; Yanqing Sun; Mei-Jie Zhang; Tina Kold Jensen
Journal:  Biometrika       Date:  2010-03       Impact factor: 2.445

7.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

8.  Flexible competing risks regression modeling and goodness-of-fit.

Authors:  Thomas H Scheike; Mei-Jie Zhang
Journal:  Lifetime Data Anal       Date:  2008-08-28       Impact factor: 1.588

  8 in total
  33 in total

1.  Hierarchical likelihood inference on clustered competing risks data.

Authors:  Nicholas J Christian; Il Do Ha; Jong-Hyeon Jeong
Journal:  Stat Med       Date:  2015-08-16       Impact factor: 2.373

2.  Donor and recipient sex in allogeneic stem cell transplantation: what really matters.

Authors:  Haesook T Kim; Mei-Jie Zhang; Ann E Woolfrey; Andrew St Martin; Junfang Chen; Wael Saber; Miguel-Angel Perales; Philippe Armand; Mary Eapen
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

3.  Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Yvette L Kasamon; Christopher G Kanakry; Javier Bolaños-Meade; Hua-Ling Tsai; Margaret M Showel; Jennifer A Kanakry; Heather J Symons; Ivana Gojo; B Douglas Smith; Maria P Bettinotti; William H Matsui; Amy E Dezern; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Douglas E Gladstone; Lode J Swinnen; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

4.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

5.  Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Authors:  Lindsey R Lombardi; Christopher G Kanakry; Marianna Zahurak; Nadira Durakovic; Javier Bolaños-Meade; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Robert A Brodsky; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Leuk Lymphoma       Date:  2015-10-12

6.  Penalized variable selection in competing risks regression.

Authors:  Zhixuan Fu; Chirag R Parikh; Bingqing Zhou
Journal:  Lifetime Data Anal       Date:  2016-03-26       Impact factor: 1.588

7.  Modeling sleep fragmentation in sleep hypnograms: An instance of fast, scalable discrete-state, discrete-time analyses.

Authors:  Bruce J Swihart; Naresh M Punjabi; Ciprian M Crainiceanu
Journal:  Comput Stat Data Anal       Date:  2015-09       Impact factor: 1.681

8.  Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

Authors:  Raphael Carapito; Nicolas Jung; Marius Kwemou; Meiggie Untrau; Sandra Michel; Angélique Pichot; Gaëlle Giacometti; Cécile Macquin; Wassila Ilias; Aurore Morlon; Irina Kotova; Petya Apostolova; Annette Schmitt-Graeff; Anne Cesbron; Katia Gagne; Machteld Oudshoorn; Bronno van der Holt; Myriam Labalette; Eric Spierings; Christophe Picard; Pascale Loiseau; Ryad Tamouza; Antoine Toubert; Anne Parissiadis; Valérie Dubois; Xavier Lafarge; Myriam Maumy-Bertrand; Frédéric Bertrand; Luca Vago; Fabio Ciceri; Catherine Paillard; Sergi Querol; Jorge Sierra; Katharina Fleischhauer; Arnon Nagler; Myriam Labopin; Hidetoshi Inoko; Peter A von dem Borne; Jürgen Kuball; Masao Ota; Yoshihiko Katsuyama; Mauricette Michallet; Bruno Lioure; Régis Peffault de Latour; Didier Blaise; Jan J Cornelissen; Ibrahim Yakoub-Agha; Frans Claas; Philippe Moreau; Noël Milpied; Dominique Charron; Mohamad Mohty; Robert Zeiser; Gérard Socié; Seiamak Bahram
Journal:  Blood       Date:  2016-08-22       Impact factor: 22.113

9.  Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Authors:  Yvette L Kasamon; Javier Bolaños-Meade; Gabrielle T Prince; Hua-Ling Tsai; Shannon R McCurdy; Jennifer A Kanakry; Gary L Rosner; Robert A Brodsky; Karlo Perica; B Douglas Smith; Douglas E Gladstone; Lode J Swinnen; Margaret M Showel; William H Matsui; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Michael A McDevitt; Ivana Gojo; Amy E Dezern; Satish Shanbhag; Mark J Levis; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Richard J Jones
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

10.  Is Anesthesia Technique Associated With a Higher Risk of Mortality or Complications Within 90 Days of Surgery for Geriatric Patients With Hip Fractures?

Authors:  Vimal Desai; Priscilla H Chan; Heather A Prentice; Gary L Zohman; Glenn R Diekmann; Gregory B Maletis; Brian H Fasig; Diana Diaz; Elena Chung; Chunyuan Qiu
Journal:  Clin Orthop Relat Res       Date:  2018-06       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.